| Followers | 39 |
| Posts | 2870 |
| Boards Moderated | 0 |
| Alias Born | 12/06/2003 |
Friday, May 04, 2018 8:41:16 AM
There are obviously other treatment options available.
Oh really?
Could you then be so kind as to list all the other veterinary drugs available for overcoming dogs' loss of appetite? Ghrelin is not a new drug but the availability for dogs in an FDA-approved formula is quite new. The drug has had a lengthy and controversial history.
No one can doubt there are many drugs purporting to treat osteoporosis in dogs - a hideous killer - successfully but only one is a very promising EP4 receptor agonist that took our Border Collie mutt off a death watch. My wife says the dog is regaining a bit of the terrible energy that had her biting the heads off electrical cords like they were snakes when she was the typical Border Collie indoor tornado as pups. So far our cords seem safe but the dog biscuits aren't.
Eli Lilly subsidiary Elanco sells the Galliprant so sales by PETX are, and will remain, zero but other drugs are doing swell, as is Galliprant.
So why the dreadful headlines?
PETX CEO St. Peter claims it is a matter of inventory problems of new drugs.
Is it all a pack of lies?
- How would I know?
Best, Terry
Oh really?
Could you then be so kind as to list all the other veterinary drugs available for overcoming dogs' loss of appetite? Ghrelin is not a new drug but the availability for dogs in an FDA-approved formula is quite new. The drug has had a lengthy and controversial history.
No one can doubt there are many drugs purporting to treat osteoporosis in dogs - a hideous killer - successfully but only one is a very promising EP4 receptor agonist that took our Border Collie mutt off a death watch. My wife says the dog is regaining a bit of the terrible energy that had her biting the heads off electrical cords like they were snakes when she was the typical Border Collie indoor tornado as pups. So far our cords seem safe but the dog biscuits aren't.
Eli Lilly subsidiary Elanco sells the Galliprant so sales by PETX are, and will remain, zero but other drugs are doing swell, as is Galliprant.
So why the dreadful headlines?
PETX CEO St. Peter claims it is a matter of inventory problems of new drugs.
Is it all a pack of lies?
- How would I know?
Best, Terry
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
